Syndax Pharmaceuticals’ Promising AML Study Update: Key Insights for Investors

Syndax Pharmaceuticals Inc. ((SNDX)) announced an update on their ongoing clinical study.

Study Overview: Syndax Pharmaceuticals Inc. is conducting a Phase 1 study titled A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes. The study aims to assess the safety and effectiveness of SNDX-5613 combined with chemotherapy in treating acute myeloid leukemia (AML) with specific genetic alterations.

Intervention/Treatment: The study tests SNDX-5613, an experimental drug, in combination with a chemotherapy regimen and high-dose cytarabine (HiDAC). The goal is to determine the optimal dose and evaluate its safety and efficacy in AML patients.

Study Design: This interventional study follows a sequential model without masking, focusing on treatment as the primary purpose. Participants receive escalating doses of SNDX-5613 with chemotherapy during induction, followed by consolidation with HiDAC and maintenance monotherapy with SNDX-5613.

Study Timeline: The study began on January 12, 2024, with the latest update submitted on July 22, 2025. These dates mark the study’s progress and ongoing recruitment status, indicating active research efforts.

Market Implications: Positive updates from this study could boost Syndax Pharmaceuticals’ stock performance by enhancing investor confidence in its pipeline. Success in this trial may position Syndax favorably against competitors in the AML treatment market, potentially leading to increased market share.

The study is currently ongoing, with further details available on the ClinicalTrials portal.